AnGes, Inc. (TYO:4563)

Market Cap	32.97B
Revenue (ttm)	710.00M
Net Income (ttm)	-28.59B
Shares Out	362.36M
EPS (ttm)	-97.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,991,500
Average Volume	17,866,785
Open	94.00
Previous Close	91.00
Day's Range	89.00 - 94.00
52-Week Range	46.00 - 120.00
Beta	1.01
RSI	51.11
Earnings Date	Nov 7, 2025

About AnGes

AnGes, Inc. engages in the research and development of gene-based medical products. It develops HGF gene therapy product for the treatment of ischemic diseases; NF-κB Decoy Oligo DNA for chronic discogenic lumber back pain; and DNA vaccines for the treatment of hypertension and cervical intraepithelial neoplasia, as well as intranasal formulation of the COVID-19 vaccine. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 55
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4563

Financial Performance

In 2024, AnGes's revenue was 643.00 million, an increase of 323.03% compared to the previous year's 152.00 million. Losses were -28.13 billion, 278.2% more than in 2023.